Anti-BAFF-anti-IL-17 bispecific monoclonal antibody - Eli Lilly

Drug Profile

Anti-BAFF-anti-IL-17 bispecific monoclonal antibody - Eli Lilly

Latest Information Update: 10 Mar 2016

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antibodies
  • Mechanism of Action B cell activating factor inhibitors; Interleukin-17 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Immunological disorders

Most Recent Events

  • 25 Jan 2016 Phase-I clinical trials in Immunological disorders in USA (unspecified route) before January 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top